• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Human Longevity makes a move toward Nasdaq with potential SPAC deal, but nothing's...

cafead

Administrator
Staff member
  • cafead   Jun 21, 2022 at 12:02: PM
via Anti-aging company Human Longevity, founded by pioneering genomic researcher Craig Venter, is one step closer, potentially, to becoming a public company.

The startup put out a press release Monday afternoon saying it has signed a “letter of intent” to reverse merge with a SPAC run by former Credit Suisse CEO Tidjane Thiam, known as Freedom Acquisition I Corp. If none of the SPAC investors redeem their shares and pull out at the float price of $10, Human Longevity will receive $345 million.

article source